Intellectual property protection and freedom to operate for ViaCyte and our partners
ViaCyte’s patent portfolio includes hundreds of issued patents worldwide, and patent terms in the space extend for the next two decades or more. Patents have been issued in the United States and many countries around the world, including Australia, Belgium, Canada, China, Denmark, France, Germany, Hong Kong, Iceland, India, Ireland, Israel, Italy, Japan, Mexico, Netherlands, New Zealand, Poland, Republic of Korea, Russia, Singapore, South Africa, Spain, Sweden, Switzerland, and the United Kingdom.
ViaCyte’s patent portfolio covers many of the intermediary cell types generated when human pluripotent stem cells progress along the differentiation pathway to pancreatic cells. ViaCyte has proprietary protocols for generating pancreatic progenitors and pancreatic endocrine cells at various stages of differentiation.
Type on the line above then press the Enter/Return key to submit a new search query